Cladribine (2-chloro-2′-deoxy-β-d-adenosine) is a 2′-deoxyadenosine analogue, approved by the FDA for the treatment of hairy cell leukemia and more recently has been proved for therapeutic against many autoimmune diseases as multiple sclerosis. The biosynthesis of this compound using Thermomonospora alba CECT 3324 as biocatalyst is herein reported. This thermophilic microorganism was successfully entrapped in polyacrylamide gel supplemented with nanoclays such as bentonite. The immobilized biocatalyst (T. alba-Ac-Bent 1.00 %), was able to biosynthesize cladribine with a conversion of 89 % in 1 h of reaction and retains its activity for more than 270 reuses without significantly activity loss, showing better operational stability and mechanical properties than the natural matrix. A microscale assay using the developed system, could allow the production of at least 181 mg of cladribine in successive bioprocesses.

克拉屈滨 (2-chloro-2'-deoxy-β- d - adenosine) 是一种 2'-脱氧腺苷类似物，已被 FDA 批准用于治疗毛细胞白血病，最近已被证明可用于治疗多种自身免疫性疾病，如多种自身免疫性疾病。硬化。本文报道了使用Thermomonospora alba CECT 3324 作为生物催化剂的该化合物的生物合成。这种嗜热微生物被成功地包裹在聚丙烯酰胺凝胶中，并辅以纳米粘土，如膨润土。固定化生物催化剂（T. alba-Ac-Bent 1.00 %)，能够生物合成克拉屈滨，反应 1 小时内转化率为 89 %，并在重复使用 270 多次后仍保持其活性而没有显着的活性损失，显示出比天然基质更好的操作稳定性和机械性能。使用开发的系统进行微量分析，可以在连续的生物过程中生产至少 181 毫克克拉屈滨。